|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:available_in
|
tablet form
|
|
gptkbp:brand
|
gptkb:Harvoni
|
|
gptkbp:clinical_trial
|
C-Edge study
C-SURFER study
ION-1 study
ION-3 study
|
|
gptkbp:contains
|
gptkb:ledipasvir
gptkb:sofosbuvir
|
|
gptkbp:contraindication
|
severe liver disease
|
|
gptkbp:dosage_form
|
90 mg ledipasvir and 400 mg sofosbuvir
|
|
gptkbp:duration
|
12 weeks
|
|
gptkbp:form
|
oral tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Harvoni
|
|
gptkbp:indication
|
chronic hepatitis C genotype 1
chronic hepatitis C genotype 4
chronic hepatitis C genotype 6
|
|
gptkbp:ingredients
|
gptkb:ledipasvir
gptkb:sofosbuvir
|
|
gptkbp:interacts_with
|
gptkb:phenytoin
gptkb:St._John's_Wort
gptkb:carbamazepine
gptkb:rifampin
gptkb:dexamethasone
|
|
gptkbp:invention
|
2028
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:marketed_as
|
gptkb:2014
|
|
gptkbp:patient_population
|
adults
pediatric patients over 12 years
|
|
gptkbp:previous_name
|
no
|
|
gptkbp:price
|
varies by region
approximately $94,500 for a 12-week course
|
|
gptkbp:related_products
|
gptkb:Sovaldi
gptkb:Epclusa
gptkb:Mavyret
gptkb:Zepatier
Vosevi
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:route_of_administration
|
once daily
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
headache
nausea
allergic reactions
diarrhea
rash
insomnia
itching
liver problems
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:success_rate
|
95% or higher
|
|
gptkbp:treatment
|
sustained virologic response
cure rate
|
|
gptkbp:used_for
|
treatment of hepatitis C
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
|
|
gptkbp:bfsLayer
|
4
|